Supplementary Data from Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer

Le résumé fourni par la source

Supplementary Table S1 to S4 and Supplementary Figure S1 to S3 Supplementary Table S1. Classification of BRAF variants identified in this study Supplementary Table S2. Patient characteristics based on BRAF classification Supplementary Table S3. Characteristics of patients treated with anti-EGFR antibody therapy Supplementary TableS4. Response to anti-EGFR antibody therapy based on BRAF classification and the sidedness of the tumor Supplementary Fig. S1. CONSORT diagram. Supplementary Fig. S2. Onco-print showing the alterations identified in 96 specimens from 118 patients analyzed for OS. Supplementary Fig. S3. OS in all patients with BRAFnon-V600 mutation (A) and stratified by RASmutation (B), or stratified by BRAFclassification in patients with RASwild-type tumors (C).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.